SAEs · people with multiple sclerosis
Antioxidant showed no clear difference in SAEs (assessed as number of participants experiencing a SAE) compared with placebo (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Polyunsaturated fatty acid (PUFA) showed no clear difference in global impression of deterioration (investigator defined global… compared with monounsaturated fatty acid (MUFA) (low certainty).
1 finding from 1 review
MRI activity ‐ not measured · people with multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · people with multiple sclerosis
1 finding from 1 review
Relapse · people with multiple sclerosis
Omega‐3 showed no clear difference in relapse(assessed as number of participants experiencing relapse) compared with omega‐6 (low certainty).
1 finding from 1 review
Change in validated disability scale ( · people with multiple sclerosis
1 finding from 1 review
Global impression of deterioration (investigator defined global impression of deterioration) · people with multiple sclerosis
Omega‐3 showed no clear difference in global impression of deterioration (investigator defined global… compared with omega‐6 (moderate certainty).
1 finding from 1 review
MRI activity(assessed by new gadolinium‐enhancing lesions) · people with multiple sclerosis
1 finding from 1 review
Children's fruit and vegetable intake (not measured) · children aged 3 to 11 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Children's SSB intake (not measured) · children aged 3 to 11 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Physical activity · children aged 3 to 11 years
1 finding from 1 review
Time in MVPA · children aged 3 to 11 years
1 finding from 1 review
Adverse effects (not measured) · children aged 3 to 11 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Children's percentage of total energy intake from saturated fat Measured by food frequency questionnaire and 24‐hour recall · children aged 3 to 11 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Children's sodium intake (not measured) · children aged 3 to 11 years
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of weight gain (g/kg/day) · promoting growth and development in very low birth weight infants receiving human milk
1 finding from 1 review
Rate of weight gain (g/kg/day) · promoting growth and development in very low birth weight infants receiving human milk
1 finding from 1 review
Linear growth (cm/week) · promoting growth and development in very low birth weight infants receiving human milk
1 finding from 1 review
Growth velocity, head circumference, mm/d, end of intervention · promoting growth and development in very low birth weight infants receiving human milk
1 finding from 1 review